In vitro to in vivo extrapolation for high throughput prioritization and decision making.

In vitro chemical safety testing methods offer the potential for efficient and economical tools to provide relevant assessments of human health risk. To realize this potential, methods are needed to relate in vitro effects to in vivo responses, i.e., in vitro to in vivo extrapolation (IVIVE). Currently available IVIVE approaches need to be refined before they can be utilized for regulatory decision-making. To explore the capabilities and limitations of IVIVE within this context, the U.S. Environmental Protection Agency Office of Research and Development and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods co-organized a workshop and webinar series. Here, we integrate content from the webinars and workshop to discuss activities and resources that would promote inclusion of IVIVE in regulatory decision-making. We discuss properties of models that successfully generate predictions of in vivo doses from effective in vitro concentration, including the experimental systems that provide input parameters for these models, areas of success, and areas for improvement to reduce model uncertainty. Finally, we provide case studies on the uses of IVIVE in safety assessments, which highlight the respective differences, information requirements, and outcomes across various approaches when applied for decision-making.

Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.

Pictilisib, a weakly basic compound, is an orally administered, potent, and selective pan-inhibitor of phosphatidylinositol 3-kinases for oncology indications. To investigate the significance of high-fat food and gastric pH on pictilisib pharmacokinetics (PK) and enable label recommendations, a dedicated clinical study was conducted in healthy volunteers, whereby both top-down (population PK, PopPK) and bottom-up (physiologically based PK, PBPK) approaches were applied to enhance confidence of recommendation and facilitate the clinical development through scenario simulations. The PopPK model identified food (for absorption rate constant (Ka )) and proton pump inhibitors (PPI, for relative bioavailability (Frel ) and Ka ) as significant covariates. Food and PPI also impacted the variability of Frel . The PBPK model accounted for the supersaturation tendency of pictilisib, and gastric emptying physiology successfully predicted the food and PPI effect on pictilisib absorption. Our research highlights the importance of applying both quantitative approaches to address critical drug development questions.

A detailed resonance Raman spectrum of Nickel(II)-substituted Pseudomonas aeruginosa azurin.

Nickel(II) and cobalt(II) derivatives of the blue copper protein Pseudomonas aeruginosa azurin have been studied by resonance Raman (RR) spectroscopy at liquid-nitrogen temperatures. Vibrational assignments for the observed RR bands of Ni(II)-azurin have been made through a study of (62)Ni-substituted azurin. A comparison of Ni(II)-azurin RR spectra with those of the wild type (Cu-containing) protein showed Ni(II)-S(Cys) stretching vibrations, nu(Ni-S)(Cys), at substantially lower frequencies (approximately 360 versus approximately 400 cm(-1), respectively), indicating that the Ni(II)-S(Cys) bond is much weaker than the corresponding Cu(II)-S(Cys) bond. Resonance enhanced predominantly nu(Ni-N)(His) modes indicate that the metal-N(His) bond distances in the Ni(II) derivative are the same as those in native azurin. The vibrational data also confirm a tetrahedral disposition of ligands about the metal in Ni(II)-azurin found in the protein crystallographic structures. As expected, excitation profile measurements on Ni(II)-azurin show that the nu(Ni-S)(Cys) assignable modes give maxima at the 440-nm absorption band, which confirms a S(Cys) --> Ni(II) charge-transfer origin of the 440-nm electronic transition in Ni(II)-substituted azurin.